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A body of evidence has accumulated indicating diabetes is associated with cognitive impairments.
Effective strategies are therefore needed that will delay or prevent the onset of these diabetes-related
deﬁcits. In this regard, dietary modiﬁcation with the naturally occurring compound, docosahexaenoic
acid (DHA), holds signiﬁcant promise as it has been shown to have anti-inﬂammatory, anti-oxidant, and
anti-apoptotic properties. The hippocampus, a limbic structure involved in cognitive functions such as
memory formation, is particularly vulnerable to the neurotoxic effects related to diabetes, and we have
previously shown that streptozotocin-induced diabetes alters hippocampal gene expression, including
genes involved in synaptic plasticity and neurogenesis. In the present study, we explored the effects of
dietary supplementation with DHA on hippocampal gene expression in C57Bl/6 diabetic mice. Diabetes
was established using streptozotocin (STZ) and once stable, the dietary intervention group received
AIN93G diet supplemented with DHA (50 mg/kg/day) for 6 weeks. Microarray based genome-wide
expression analysis was carried out on the hippocampus of DHA supplemented diabetic mice and
conﬁrmed by real time polymerase chain reaction (RT-qPCR). Genome-wide analysis identiﬁed 353
differentially expressed genes compared to non-supplemented diabetic mice. For example, six weeks of
dietary DHA supplementation resulted in increased hippocampal expression of Igf II and Sirt1 and
decreased expression of Tnf-a, Il6, Mapkapk2 and ApoE, compared to non-supplemented diabetic mice.
Overall, DHA supplementation appears to alter hippocampal gene expression in a way that is consistent
with it being neuroprotective in the context of the metabolic and inﬂammatory insults associated with
diabetes.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
While a decline in cognitive function and memory is considered
to be a normal consequence of ageing [1], disease conditions such
as diabetes also lead to the development of cognitive dysfunction
and memory impairments [2e5]. Both type I and II diabetes
are associated with memory deﬁcits, and the hippocampus isthe Priority Research Centre
castle, Australia.
ces & Pharmacy, University of
M.L. Garg).
Ltd. This is an open access article uparticularly vulnerable, with structural and functional alterations
being caused by the disease processes [6e8]. For example,
morphological changes, such as dendrite atrophy (reduced den-
dritic length and number of branch points), have been observed in
experimental models of diabetes [9,10]. Diabetes also leads to
abnormal neurotransmitter release in the hippocampus [11]. Lastly,
neurogenesis, the processes through which new neurons are
generated and integrated into existing circuits, and that is thought
to be crucial for normal cognitive functions, is impaired in animal
models of diabetes [12]. Indeed, impaired hippocampal synaptic
plasticity and neurogenesis appear to be major factors in the
cognitive deﬁcits associated with diabetes [13]. While the under-
lying cellular mechanisms for these impairments remain to be fully
elucidated, we have started to characterise these mechanisms andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Fatty acid levels in the erythrocytes of DHA supplemented diabetic group and non-
supplemented diabetic group.
Common name Lipid
name
Diabetic
(n ¼ 10)
DHA
(n ¼ 10)
P value*
Palmitic acid C16:0 23.8 ± 0.9 32.9 ± 2.7 <0.0001
Palmitoleic acid C16:1n-7 0.9 ± 0.3 1.6 ± 0.8 0.0366
Stearic acid C18:0 12.1 ± 1.2 12.2 ± 1.8 0.846
Oleic acid C18:1n-9 21.9 ± 1.9 20.6 ± 1.9 0.346
cis-vaccenic acid C18:1n-7 2.4 ± 0.3 3 ± 0.5 0.531
Linoleic acid C18:2n-6 8.4 ± 0.8 5.8 ± 0.3 0.0024
Arachidonic acid C20:4n-6 21.3 ± 0.9 6.2 ± 0.9 <0.0001
Eicosapentaenoic acid C20:5n-3 0.124 ± 0.02 4.4 ± 0.76 <0.001
Docosahexaenoic acid C22:6n-3 5.8 ± 0.4 9 ± 1.7 0.0264
Lignoceric acid C24:0 1.1 ± 0.1 1.7 ± 0.6 0.112
Nervonic acid C24:1n-9 2.1 ± 0.2 1.6 ± 0.6 0.048
*P values were obtained using independent samples t-test for diabetic and DHA
supplemented diabetic group.
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expression of genes that are important for both synaptic plasticity
and neurogenesis [14].
The restoration of normal hippocampal synaptic plasticity and
neurogenesis is therefore an important goal for the prevention of,
or recovery from, diabetes associated cognitive decline. Of the
various substances that have been shown to promote hippocampal
and overall cognitive function, docosahexaenoic acid (DHA) is
showing considerable promise [15]. DHA is a long chain omega-3
polyunsaturated fatty acid (LnC-PUFA) and an integral component
of neural membrane phospholipids. DHA inﬂuences membrane
ﬂuidity, modulates signal transduction and also receptor afﬁnity,
and thereby affects multiple brain functions [16]. Several epide-
miological studies have shown a close relationship between DHA
and cognition, with low plasma DHA levels associated with
cognitive deﬁcits in healthy elderly subjects and also in patients
suffering from neurodegenerative disorders such as Alzheimer's
disease (AD) [17e20]. Additionally, preclinical studies have shown
that DHA enhances performance in learning and memory tasks in
aged animals [21], and it also improves cerebral blood ﬂow [22].
DHA is highly concentrated in the brain and has been shown to
have anti-oxidant, anti-inﬂammatory, and anti-apoptotic proper-
ties [23]. Importantly, a high dietary intake of DHA leads to accu-
mulation of DHA in brain membrane phospholipids [21]. The
potential beneﬁcial effects of DHA to cognitive function have been
reported [24e27], however, there are no studies exploring the ef-
fects of DHA on hippocampal gene expression in diabetes. This type
of study could provide insight into the underlying molecular
mechanism by which DHA could confer its beneﬁcial effects. In the
present study we employ streptozotocin (STZ) induced diabetic
animals to study the effect of dietary supplementationwith DHA on
hippocampal gene expression.
Materials and methods
Subjects
Seven week-old, male C57BL/6 mice (University of Newcastle;
weighing 20e25 g upon arrival) were individually housed in a
temperature and humidity controlled environment under a 12 h
light/dark cycle, with food and water available ad libitum. All pro-
cedures were performed in strict accordance with protocols
approved by University of Newcastle Animal Care and Ethics
Committee, the New South Wales Animal Research Act and Regu-
lations, and the Australian code of practice for care and use of an-
imals for scientiﬁc purposes.
Methods and treatment
After one week of acclimatization, animals received daily in-
jections of streptozotocin (STZ; Sigma; 50 mg/kg i.p.) freshly dis-
solved in 100 ml of 0.5 M sodium citrate buffer for ﬁve consecutive
days as previously described [14]. Blood glucose levels were
determined from saphenous vein blood using an Accu-Check
Integra (Roche Diagnostics Mannheim, Germany). After three
weeks of STZ administration, animals exhibiting blood glucose
levels 15 mM were considered to be diabetic. Following conﬁr-
mation of a diabetic state, animals were put on a semi-pure diet
(AIN93G; Specialty Feeds Western Australia), which satisﬁes all
nutritional requirements. For DHA supplementation (EPAX,
1050TG), the animals received 50 mg/kg/day of DHA mixed with
AIN93G diet every day for a period of 6 weeks. Blood glucose levels
and bodyweight weremonitoredweekly for six weeks. Food intake
was monitored and recorded every week, and all animals had ad
libitum access to drinking water.Animal sacriﬁce and tissue harvesting
At the end of the six-week period of stable diabetes and dietary
supplementation, animals were overdosed with pentabarbitone
and the brains were rapidly removed, immediately cooled in ice-
cold PBS and frozen in dry-ice chilled isopentane. Tissue was
stored at 80 C until required. Ten mm thick, coronal hippocampal
sections were obtained by cryosection, mounted on nuclease-free
glass microscope slides and stored at 80 C until further use.
Blood was drawn from saphenous vein and processed for gas
chromatography to analyse erythrocyte fatty acid analysis (see
Table 1).
Erythrocyte fatty acid analyses
The fatty acid composition of erythrocytes was determined ac-
cording to modiﬁed Lepage and Roy (1986) method where acetyl
chloride methylation procedure is appropriated. Fatty acid methyl
esters were quantiﬁed using gas chromatography. The identity of
each fatty acid peak was ascertained by comparison of the peak's
retention time with the retention times of synthetic standards of
known fatty acid composition (Nu Check Prep, Elysian, MN, USA).
The relative amount of each fatty acid was quantiﬁed by integrating
the area under the peak and dividing the result by the total area for
all fatty acids. Fatty acid results are reported as percentage of total
fatty acids.
RNA extraction
Sections were rinsed in ice-old PBS (DEPC treated) and then
ﬁxed in ice-cold ethanol (100%) for 3 min. Whole hippocampi were
dissected from sections at approximately 250 mm intervals through
the rostrocaudal extent of the hippocampus. Total RNA was
extracted from hippocampal tissue pooled for each animal.
Contaminating genomic DNA (gDNA) removed in solution by
DNase-I digestion using Qiagen's RNeasy mini kit and DNase re-
agents, according to the manufacturer's instructions. The concen-
tration of DNase treated RNA was determined by UV absorbance
spectrophotometry (Thermo Scientiﬁc Nanodrop 1000).
Microarray proﬁling
Gene expression proﬁling was carried out by the Australian
Genome Research Facility (AGRF, Australia). Approximately 200 ng
of total RNAwas prepared for hybridization to Illumina MouseWG-
6 v2.1 Expression microarrays. Expression data was ﬁrst analysed
using Illumina's Genome studio 2010.2 software and incorporated
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average signal intensity of 100, and statistical signiﬁcance as
determined by ANOVA, were criteria used to identify genes of
interest.
Reverse transcription and q RT-PCR
Reverse transcription
Reverse transcription was performed using Superscript III
(Invitrogen, Australia), according to manufacturer's instructions.
Brieﬂy, 200 ng of total RNA, 1 ml oligo(dT18) primer, 1 ml of 10 mM
dNTP, and molecular grade water to 13 ml, were mixed and heated
for 5min at 65 C for 5min, the chilled on ice for 1min. Next 4 ml 5
ﬁrst strand buffer, 1 ml of 0.1m DTT,1 ml RNaseOUT (40 U/ml) and 1 ml
of superscript, were added and the mixture incubated for 60 min at
50 C, followed by a 70 C enzyme inactivation step for 15 min.
Reverse transcription, without reverse transcriptase (RT), was
also performed to assess gDNA contamination.
Real-time qPCR
All gene transcript information was obtained from Ensembl
(www.ensembl.org). qPCR primers (Table 4) were designed using
NCBI's primer design tool (http://www.ncbi.nlm.nih.gov/tools/
primer-blast/). qPCR volumes were 12 ml, contained 1 ng cDNA,
and were run in triplicate on an ABI 7500 real time PCR system
(Applied Biosystems, USA). qPCR data was analysed using Applied
Biosystems 7500 sequence Detection software (version 1.4). For
each gene, all samples, including water controls, were run on a
single qPCR plate. For each animal, the delta Ct (DCt, threshold
cycle) was determined for the gene of interest relative to the
average of two house-keeping genes, succinate dehydrogenase
(SDH) and beta actin. For each gene, the DDCt method was used to
compare diabetic and diabetic plus DHA group [28].
Statistics
All statistical analyses were performed for qPCR were per-
formed using PASW statistics software (version 18; SPSS Inc., Chi-
cago, IL USA). Statistical signiﬁcance was assessed using one-way
analysis of variance (ANOVA). Results were considered statistically
signiﬁcant if the observed signiﬁcance level was 0.05. As we have
previously reported ﬁndings for the control and diabetic conditions
[14], comparisons in the present study are between the diabetes
plus DHA group and the previous diabetes group [14].
Results
Blood glucose and body weight
The diabetic plus DHA group showed an increase in blood
glucose levels three weeks after STZ administration. All animals inTable 2
List of genes whose expressionwas affected by diabetes relative to non-diabetic
by DHA supplementation.
Gene names
Apolipoprotein E
Insulin like growth factor 2
Sirtuin 1
Tumour necrosis factor- alpha inducing protein 1
Mitogen activated protein kinase activating protein kinase 2
Interleukin 1 beta
Interleukin 20
Interleukin 6 signal transducer
Phosphoinositide-3-kinase, regulatory subunit 2the group that exhibited blood glucose levels 15 mM were
considered diabetic. The average (±SEM) blood glucose levels in the
diabetes plus DHA group was 18.7 ± 1.47 mM. There was not a
signiﬁcant difference in blood glucose levels between the diabetes
and the diabetes plus DHA group (P ¼ 0.609). Also, there was no
signiﬁcant difference in body weight between the diabetes and the
DHA supplemented diabetic group (P ¼ 0.800).
Erythrocyte fatty acid
In response to DHA supplementation, erythrocyte fatty acid
analysis showed signiﬁcant increase in DHA (P ¼ 0.0264) and EPA
(P < 0.001) in the DHA supplemented group. A signiﬁcant reduction
in arachidonic acid was seen in the DHA supplemented group as
opposed to the non-supplemented diabetic group (P < 0.0001) (see
Table 1).
Genome wide gene expression analysis
Using the criteria described above, 353 genes were differentially
expressed in the hippocampus of the DHA supplemented diabetic
group compared to the non-supplemented diabetic group. Twenty-
one genes had increased expression and 332 (Supplementary table)
had decreased expression. Genes that were signiﬁcantly differen-
tially expressed in the hippocampus of diabetic animals compared
to non-diabetic controls, and that had this diabetes-induced change
in expression either normalized or exacerbated by DHA, are shown
in Table 2.
Pathway analysis
Pathways associated with diet induced gene expression changes
To garner a better understanding of diet-induced changes in
hippocampal gene expression, and to assess potential biological
function, the list of differentially expressed genes obtained from
microarray analysis was subjected to pathways analysis using
Database for Annotation, Visualization, and Integrated Discovery
(DAVID) [29]. DAVID analyses gene lists to statistically determine
whether there is enrichment for genes that belong to a priori-
deﬁned gene sets. This analysis found 5 signiﬁcantly (<0.05)
enriched pathways (see Table 3), using Kyoto Encyclopedia of Genes
and Genomes (KEGG). The most signiﬁcantly enriched pathways in
the DHA supplemented group were the Mapk and Jak/Stat signal-
ling pathways.
Conﬁrmation by RT-qPCR
A subset of genes was chosen for RT-qPCR conﬁrmation. Sig-
niﬁcant increases in Igf II (3.31 fold) and Sirt1 (1.81fold) and de-
creases in expression of ApoE (1.38 fold), and Tnf-a (1.76 fold)
were conﬁrmed (Fig. 1).controls, and that were either partly or wholly normalised or exacerbated,
Symbol Fld change DHA/Diab
ApoE Y1.2
Igf2 [1.6
Sirt1 [1.5
Tnfaip1 Y1.6
Mapkapk2 Y1.6
Il1b Y1.8
Il20 Y1.5
Il6st Y1.6
Pi3kr2 [1.6
Table 3
List of pathways identiﬁed by KEGG pathway analysis, showing those pathways that were enriched in the hippocampus of the DHA supplemented diabetic group, relative to
the non-supplemented diabetic group.
Pathways P-value* Fold enrichment Benjamani Genes
MAPK signalling pathway 0.0011 4.1 0.084 Mapkapk2, Dusp9, fgf2, Grb2, Il1b, Mef2c, Ntrk1, Ptpn7, Max
Jak-STAT signalling pathway 0.0012 5.6 0.049 Csf2rb2, Grb2, Ifnb1, Il13ra2, Il20, Il6st, Stat3
Pathways in cancer 0.013 3 0.31 asp9, Fgf2, Grb2, Ntrk1, Ptgs2, Max, Stat3, Wnt5a
Alzheimer's disease 0.015 4 0.26 ApoE, Bad, Casp9, Il1, CxI, CxIV
Apoptosis 0.032 5.6 0.42 asp9, Csf2rb2, Il1b, Ntrk1
Table 4
List of qPCR primers.
Target gene Forward (50e30) Reverse (50e30)
Succinate dehydrogenase GCAGAGCCTGTGCCCTGAGC CCCACACGGAACACTGCAGCA
Beta actin TGTGCTGCTCACCGA TGGCTACGTACATGG
Sirt1 GCAGATTAGTAAGCGGCTTGAGGGT TGGCATGTGCCACTGTCACTGTT
Apolipoprotein E GCTGCAGAGCTCCCAAGTCACAC TTCCTCCAGCTCCTTTTTGTAAGCC
Igf2 CGCCGGCTTCCAGGTACCAAT ACACGGCGAAGGCCAAAGAGATG
Tnf-a CAGAGGTGTGCTGCACCTCGAT CGGGCCTCTGGGAATTCCACCT
J. Thomas et al. / Journal of Nutrition & Intermediary Metabolism 2 (2015) 2e7 5Discussion
The current study shows that dietary supplementation with
DHA can alter the molecular proﬁle of the hippocampus in diabetic
mice in a way that is consistent with DHA being neuroprotective.
Previous studies have shown that dietary supplementation with
DHA has beneﬁcial effects on cognition and memory and it also
promotes neuronal survival [30,31]. In the present study, mice that
were already diabetic had their diet supplementedwith DHA for six
weeks. This dietary intervention resulted in an increase in hippo-
campal insulin like growth factor II (Igf II) and Sirt1 expression and a
decrease in hippocampal expression of pro-inﬂammatory Tnf-a, Il6
and ApoE lipoprotein, relative to non-supplemented diabetic mice.
Igf II is a mitogenic polypeptide that is relatively abundant in the
hippocampus and is thought to be involved in cognitive functions.
Indeed, hippocampal Igf II levels decline with ageing, in parallel
with age-related cognitive decline [32e35]. Schmeisser et al., 2012
demonstrated the presence of Igf II and Igf II receptors in synaptic
elements of hippocampal neurons, which is consistent with the
notion that Igf II has a role in synaptic plasticity and cognitive
functions [36]. Wuarin et al., 1996, showed that Igf II expressionwas
decreased in the brains of both insulin dependent and independent
diabetic animals [37] and consistent with this, we found by qPCRFig. 1. Conﬁrmation of gene expression by RT-qPCR. Increased Igf-II and Sirt1, and
decreased Tnf-a and ApoE expression in the hippocampus of DHA (50 mg/kg/day)
supplemented STZ-induced diabetic C57BL/6 mice. Once diabetes was established and
stable, mice were fed either a control diet or one supplemented with DHA. Data are
presented as means ± SEM, relative to control diet diabetic mice. **P  0.05 (n ¼ 6/
group).analysis that STZ-induced diabetes caused a reduction in Igf II
(P ¼ 0.025). An increase in Igf II expression in the DHA supple-
mented diabetic group is particularly encouraging as Igf II has been
shown to activate Igf I and Igf II receptors to mediate memory
enhancement [34]. Additionally, Bracko et al., 2012 and Agis-Balboa
et al., 2011 have demonstrated that Igf II is a regulator of adult
hippocampal neurogenesis [38,39]. The neuroprotective effects of
the Igfs are thought to be due to the involvement of PI3k/Akt sig-
nalling pathways [40]. In this regard, our DHA supplemented dia-
betic group showed a 1.6 fold increase in expression of Pi3kr2, also
known as P85-b, a regulatory subunit of PI3k [41], which has been
shown to be crucial for PI3k-dependent memory consolidation
processes in the hippocampus [42].
The most signiﬁcantly enriched pathways, as determined by
KEGG analysis, in the DHA supplemented group, were the Mapk
and JAK/STAT signalling pathways. These pathways are involved in
pro-inﬂammatory responses and enhance apoptosis in several
neurodegenerative conditions [24]. Notably, microarray analysis
indicated a number of the pro-inﬂammatory genes in these path-
ways (Mapkapk2, Il1b, Il20, Il13ra2, & Il6st) were signiﬁcantly down
regulated in the hippocampus of DHA supplemented diabetic mice.
Previously, it was shown that Mapkapk2 deﬁciency reduced neu-
rodegeneration and neuro-inﬂammation in a Parkinson's disease
model [43], further demonstrating a role for Mapkapk2 in neuro-
inﬂammation. We also found a decrease in Tnf-a expression in
the DHA supplemented diabetic group. Tnf-a is another pro-
inﬂammatory factor and can directly trigger the death of neurons
by inhibiting Igf survival responses [44]. Therewas also a trend for a
decrease in expression of the pro-inﬂammatory cytokine, Il6 (data
not shown). Taken together, these data indicate DHA supplemen-
tation induces an anti-inﬂammatory effect in the context of dia-
betes. Increased expression of pro-inﬂammatory mechanisms in
STZ-induced diabetes has been previously reported [45,46] and
our ﬁndings support a case for DHA in limiting the potential
damage cause by inﬂammation in this type of metabolic insult.
Another gene of interest that showed a signiﬁcant increase in
expression in the DHA supplemented group was Sirt1 (silent in-
formation regulator 1). Sirt1 is a member of the sirtuin family that
encodes a class III histone deacetylase [47]. Sirt1 is expressed in
hippocampal neurons and has been shown to improve learning and
memory by activating the brain derived neurotropic factor (BDNF)
gene [48e50]. Sirt1 has been previously shown to be decreased
in the brains of old rodents [51], indicating a role for Sirt1 in age
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pocampus of DHA supplemented diabetic group as seen in the
present study may be one of the mechanisms by which DHA could
lead to cognitive improvement in diabetic condition. Both Igf and
Sirt1 are involved in hippocampal neurogenesis and synapto-
genesis, although the mechanisms that underlie this involvement
are complex and require further clariﬁcation [48,51]. Notwith-
standing this lack of mechanistic detail, our ﬁnding that DHA
supplementation increased the hippocampal expression of both Igf
and Sirt1 in diabetic but not in normal mice [27], further un-
derscores its potential as a therapeutic agent.
Lastly, we also found a decrease in ApoE expression in the DHA
supplemented, relative to non-supplemented, diabetic group. Pre-
viously, we reported an increase in ApoE expression in the hippo-
campus of STZ induced diabetic mice [14] and an increase in ApoE
expression has been suggested to be indicative of ongoing neuronal
dysfunction [52]. In the CNS, ApoE is mainly produced by astrocytes
and transports cholesterol to neurons via ApoE receptors, a process
that is crucial for synaptogenesis [53]. The decrease in ApoE
expression could be of clinical importance as ApoE is involved in
key immune responses, including the production of pro-
inﬂammatory cytokines such as Il1b. Interestingly, Il1b was one of
the down-regulated genes (1.8 fold) in the DHA supplemented
diabetic group. Liu et al. (2011) demonstrated that neurons exposed
to Il1b express elevated levels of ApoE, a ﬁnding that is similar to
that observed in neurodegenerative diseases such as AD [54].
Therefore, a signiﬁcant decrease in ApoE expression in the hippo-
campus of the DHA supplemented diabetic group is yet another
indicator of the potential beneﬁcial effects of DHA and warrants
further investigation.
Overall, the present study helps to elucidate the molecular
changes in the hippocampus of diabetic mice following dietary
supplementation with DHA. Our ﬁndings provide an important
framework for future studies to further investigate the effects of
nutritional intervention on the molecular mechanisms that cause
diabetes related cognitive dysfunction. Furthermore, our ﬁndings
underscore the potential of naturally occurring compounds such as
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